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Introduction
Management of inflammatory rheumatic disease 
has been marked by significant advances in the last two 
decades with introduction of biological therapies [1–4]. 
Administration of these medications has resulted in an 
undisputable improvement in symptoms and signs of the 
disease as well as function and quality of life in a number 
of patients with rheumatoid arthritis, ankylosing spondyli-
tis, juvenile idiopathic arthritis or psoriatic arthritis. Patho-
genesis of the diseases remains only partially elucidated. 
Inflammatory mechanisms are closely associated with var-
ious immune disturbances [5, 6], some of which affect such 
phenomena as control of apoptosis [7] or angiogenesis [8]. 
Clinical aspects of the biological therapy have been ex-
tensively investigated both in well-controlled clinical trials 
and real-life studies, including data from registers [2, 3, 9]. 
Another aspect, patient satisfaction or disadvantages of 
the therapy, is relatively little explored in published reports. 
Clinical aspects such as efficacy or safety are generally uni-
versal and apply to all similar populations of patients. On 
the other hand, satisfaction and so-called social aspects 
of medication are mostly local and related to geographical 
location, cultural traditions and the economic situation of 
the country, as well as to some other factors [5].
The present study was designed to evaluate patient 
satisfaction with biological therapy and disadvantages 
associated with this method of treatment. The term “sat-
isfaction” is not precisely defined. In general, it refers to 
a pleasant or happy feeling about something that was 
done or happened or was needed. In this meaning, satis-
faction with the medication is an outcome of the therapy 
that is significantly positively received by the patient. In 
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the present study, we used a questionnaire to evaluate 
different aspects of satisfaction, such as influence of 
medication on physical state, emotional state, finan-
cial situation of the patient, his/her professional perfor-
mance, family and sexual life as well as leisure time.
Biological therapy is Poland is administered in select-
ed centers and medication can be associated with some 
disadvantages as well. Factors that can create discon-
tent in the patients were also included in the question-
naire. The study was conducted by the Polish Society for 
Rheumatology within its Section of Recommendations 
and Clinical Initiatives.
Material and methods
The questionnaire was prepared by the authors of the 
study, and was provided to patients receiving biological 
medication of rheumatic diseases. The response was vol-
untary and anonymous. We received 1239 questionnaires 
from 23 centers administrating the medication. Eight 
questionnaires were incompletely fulfilled and were reject-
ed. The final analysis was based on 1212 questionnaires 
obtained from patients treated with biological drugs due 
to rheumatoid arthritis, ankylosing spondylitis, psoriatic 
arthritis and juvenile idiopathic arthritis. The remaining 
19 patients were receiving biological therapy due to other 
diseases (e.g. vasculitis). The last group was not included in 
the study because it consisted of patients suffering from 
various diseases and some of the patients were receiving 
the medication for an unapproved indication. The inves-
tigated questionnaires were obtained from about 20% of 
all patients with rheumatic diseases receiving biological 
medication in Poland. All included patients were receiving 
the biological therapy within the reimbursement program 
called the medicinal program of the National Health Fund 
– the state insurance company.
Results
Characteristics of patients
There were 714 (58.9%) female patients and 498 
(41.1%) male patients. All patients were 18 or more years 
old. Patients with juvenile idiopathic arthritis included in 
Table I. Demographic characteristics of investigated subjects
Feature All (%) Rheumatoid 
arthritis (%)
Ankylosing 
spondylitis (%)
Psoriatic arthritis (%) Juvenile idiopathic 
arthritis (%)
Female 714 (58.9) 485 (67.9) 130 (18.2) 52 (7.3) 47 (6.6)
Male 498 (41.1) 121 (24.3) 297 (59.6) 297 (13.1) 15 (3.0)
All 1212 (100.0) 606 (F : M = 
80.0/20.0)*
427 (F : M = 
30.4/69.6)*
117 (F : M = 44.4/55.6)* 62 (F : M = 
75.8/24.2)*
Age (years)
18–29 183 (15.2) 51 (8.4) 65 (15.2) 14 (12.0) 53 (85.5)
30–39 255 (21.0) 73 (12.0) 153 (35.8) 24 (20.5) 5 (.8.1)
40–49 239 (19.7) 111 (18.3) 94 (22.0) 31 (26.5) 3 (4.8)
50–59 332 (27.4) 207 (34.2) 87 (20.4) 38 (32.5) 0 (0.0)
60 and more 203 (16.7) 164 (27.1) 28 (6.6) 10 (8.5) 1 (1.6)
Educational level
Elementary 38 (3.1) 25 (4.1) 8 (1.9) 4 (3.4) 1 (1.6)
Vocational 242 (20.0) 136 (22.4) 80 (18.7) 20 (17.1) 6 (9.7)
High school 345 (28.5) 182 (30.0) 106 (24.8) 35 (29.9) 22 (35.5)
College level 146 (12.0) 76 (12.5) 45 (10.6) 10 (8.5) 15 (24.2)
University (not 
completed)
88 (7.3) 41 (6.8) 30 (7.0) 10 (8.5) 7 (11.3)
University
(graduated)
353 (29.1) 146 (24.2) 158 (37.0) 38 (32.6) 11 (17.7)
Unmarried 266 (22.0) 83 (13.8) 103 (24.1) 28 (23.9) 52 (83.9)
Married 708 (58.4) 339 (55.9) 289 (67.7) 71 (60.7) 9 (14.5)
Divorced 175 (14.4) 136 (22.4) 27 (6.3) 11 (9.4) 1 (1.6)
Widow/widower 63 (5.2) 48 (7.9) 8 (1.9) 7 (6.0) 0 
*female to male ratio within the group of one disease
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the study had been diagnosed a few years earlier when 
they had been children but the present study includ-
ed only those of them who were adults and continued 
medication with biological drugs when they responded 
to the questionnaire. Half of the investigated patients 
(50%) suffered from rheumatoid arthritis, 35% were be-
ing treated due to ankylosing spondylitis, and 10% and 
5% were being treated due to psoriatic arthritis and ju-
venile idiopathic arthritis, respectively. The detailed data 
of the patient population are summarized in Table I. Age 
distribution was associated with disease. Rheumatoid 
arthritis was the most common in patients aged 30–59 
while ankylosing spondylitis occurred predominantly in 
patients aged 30–39. Distribution of patients suffering 
from psoriatic arthritis was similar within the age group 
30–59, with some increase in the 50–59 year-old group, 
and, as expected, juvenile idiopathic arthritis was pre-
dominantly seen in patients aged 18–29.
Education of the patients was mostly similar in all 
subgroups representing various diseases, with some ex-
ception for ankylosing spondylitis. This younger group 
had more patients who were university graduates. Mar-
ital status of the patients with specific diseases was re-
lated to the average age of the patients. Disorders that 
are prominent in younger populations have been found 
to be more common in unmarried or married individuals 
while those occurring predominantly in older age were 
more common in divorced or widowed patients (Table I).
Distribution of the specific diseases among inhabi-
tants of villages, small towns and large cities was gener-
ally similar (Table II). 
Satisfaction
Various aspects of satisfaction of the patients were 
estimated. In all subgroups, the effect of the therapy on 
physical state was very large (Table III). Almost nine out 
of ten patients (87.8%) suffering from ankylosing spon-
dylitis considered the influence of biological therapy on 
his/her physical state as beneficial or very beneficial. 
Similar but slightly lower results were found in patients 
with rheumatoid arthritis or psoriatic arthritis. This ob-
servation is concordant with physicians’ view. The reim-
bursement plan for patients with ankylosing spondylitis 
provides an opportunity to administer biological drugs 
at an earlier stage of the disease than in patients with 
rheumatoid arthritis. Lack of efficacy or intolerance of 
two non-steroidal anti-inflammatory drugs is sufficient 
for initiation of biological therapy. Thus, the slightly 
higher rate of satisfaction found in patients with anky-
losing spondylitis may result from the effect of therapy 
on physical state when the medication is applied at an 
earlier stage of the disease as compared to other sub-
groups of investigated patients.
Sleep quality is known to be disturbed in chronic in-
flammatory disorders and in rheumatic diseases pain is 
an additional factor affecting quality of sleep. The data 
provided in Table III indicate that biological therapy is 
very beneficial in controlling sleep disturbances in inves-
tigated patients. The highest rate of a very beneficial re-
sponse to biological therapy in patients with ankylosing 
spondylitis may be related to management of so-called 
inflammatory back pain, a characteristic feature of the 
disease causing sleep disturbances in the second half 
of the night.
Table III summarizes the effect of biological thera-
py on the financial state of the patients. The obtained 
results are very similar in all subgroups representing 
various diseases. Almost half of the patients reported 
lack of such influence. A similar percentage of patients 
considered such influence as negative and positive. The 
financial state of the patients who were not employed 
and were receiving disablement pension was consid-
ered “not applicable”. Moreover, most of them were not 
interested in finding a job because it was possible that 
the disability benefit would be similar to a salary from 
the employment and in many regions of the country, 
and finding a job for some patients might be a signifi-
cant problem. Of course, such factors as profession and 
education were critical points in discussing the problem. 
Additionally, disablement pension is considered as a low 
Table II. Place of residence of patients
Place of residence All (%) Rheumatoid 
arthritis (%)
Ankylosing 
spondylitis (%)
Psoriatic arthritis 
(%)
Juvenile idiopathic 
arthritis (%)
Village 321 (26.6) 157 (25.9) 112 (26.2) 36 (30.8) 16 (25.8)
Town < 30,000 
inhabitants
198 (16.4) 99 (16.3) 67 (15.7) 23 (19.6) 9 (14.5)
Town 30,000–100,000 
inhabitants
268 (22.2) 140 (23.1) 94 (22.0) 24 (20.5) 10 (16.1)
Town > 100,000 
inhabitants
425 (34.8) 210 (34.7) 154 (36.1) 34 (29.1) 27 (43.6)
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but more stable source of income as compared to job 
position. 
The negative effect of the therapy on the financial 
state of the patients probably resulted from the cost of 
travel to the rheumatological center. Certain patients 
who were working during therapy were afraid of dis-
closing their medical condition to the employer and 
preferred to take an unpaid day off for the visit to the 
medication center than a partially paid sick-leave day. 
Correlation studies (data not shown) revealed only 
a trend (not significant) of a more beneficial effect of 
biological therapy on financial state in patients with a 
higher education level and those living in big cities than 
in those who were relatively uneducated and inhabited 
rural regions.
A beneficial or very beneficial influence of the thera-
py on family life was reported by the patients (Table III). 
There was also a substantial group of the patients who 
Table III. Effect of biological therapy on various aspects of patients’ life
Aspect of life All (%) Rheumatoid 
arthritis (%)
Ankylosing 
spondylitis (%)
Psoriatic 
arthritis (%)
Juvenile idiopathic 
arthritis (%)
Physical state
Very negative 13 (1.1) 8 (1.3) 1 (0.2) 3 (2.6) 1 (1.6)
Negative 55 (4.5) 35 (5.8) 14 (3.3) 3 (2.6) 3 (4.8)
No effect 125 (10.3) 67 (11.1) 37 (8.7) 15 (12.8) 6 (9.7)
Beneficial 610 (50.4) 311 (51.3) 218 (51.0) 45 (38.5) 36 (58.1)
Very beneficial 409 (33.7) 185 (30.5) 157 (36.8) 51 (43.5) 16 (25.8)
Sleep quality
Very negative 12 (1.0) 6 (1.0) 2 (0.5) 2 (1.7) 2 (3.2)
Negative 54 (4.5) 35 (5.8) 16 (3.7) 2 (1.7) 1 (1.6)
Lack of effect 317 (26.2) 183 (30.2) 68 (15.9) 35 (29.9) 31 (50.0)
Beneficial 503 (41.5) 256 (42.2) 177 (41.5) 45 (38.5) 25 (40.4)
Very beneficial 326 (26.8) 126 (20.8) 164 (38.4) 33 (28.2) 3 (4.8)
Patient’s view of the effect of biological therapy on his/her financial situation
Very negative 12 (1.0) 4 (0.7) 5 (1.2) 2 (1.7) 1 (1.6)
Negative 88 (7.3) 50 (8.2) 25 (5.9) 7 (6.0) 6 (9.7)
No influence 576 (47.5) 278 (45.9) 207 (48.5) 56 (47.9) 35 (56.5)
Beneficial 222 (18.3) 95 (15.7) 95 (22.2) 26 (22.2) 6 (9.7)
Very beneficial 179 (14.8) 139 (22.9) 30 (7.0) 8 (6.8) 2 (3.2)
Not applicable 135 (11.1) 40 (6.6) 65 (15.2) 18 (15.4) 12 (19.3)
Family life
Very negative 4 (0.3) 1 (0.2) 1 (0.2) 2 (1.7) 0 
Negative 20 (1.7) 12 (2.0) 5 (1.2) 2 (1.7) 1 (1.6)
No influence 303 (25.0) 172 (28.4) 84 (19.7) 23 (19.7) 24 (38.8)
Beneficial 499 (41.2) 256 (42.2) 174 (40.7) 48 (41.0) 21 (33.8)
Very beneficial 347 (28.6) 145 (23.9) 152 (35.6) 38 (32.5) 12 (19.4)
Not applicable 39 (3.2) 20 (3.3) 11 (2.6) 4 (3.4) 4 (6.4)
Ability to perform housekeeping work at home
Very negative 13 (1.1) 6 (1.0) 2 (0.5) 4 (3.4) 1 (1.6)
Negative 43 (3.5) 33 (5.4) 7 (1.6) 1 (0.9) 2 (3.2)
No influence 185 (15.3) 98 (16.2) 51 (11.9) 22 (18.7) 14 (22.6)
Beneficial 556 (45.8) 289 (47.7) 202 (47.3) 43 (36.8) 22 (35.6)
Very beneficial 385 (31.8) 164 (27.1) 157 (36.8) 45 (38.5) 19 (30.6)
Not applicable 30 (2.5) 16 (2.6) 8 (1.9) 2 (1.7) 4 (6.4)
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found no effect of administration of biologics on their 
family life. There was no significant difference between 
subgroups of the patients with various diseases. Very 
similar results were reported relating to the influence of 
the treatment on ability to perform housekeeping work 
(Table III). Small groups of the patients responded “not 
applicable”; it is assumed that they were single persons 
living without family.
Good quality of life is usually related in part to sexu-
al life. Table IV indicates a beneficial effect of biological 
therapy on sexual life. The highest positive effect of bi-
ological therapy on sexual life was reported in patients 
with ankylosing spondylitis. This disease, affecting pre-
dominantly young males, has a profound influence on 
sexual life [10–15]. Six of ten patients reported a ben-
eficial effect of the therapy. Additionally, patients with 
psoriatic arthritis, a disease associated with cutaneous 
abnormalities, may benefit from biological therapy, and 
it may result in improvement in their sexual life [16, 17].
Other aspects of quality of life are interpersonal 
relations and leisure time. Both factors are influenced 
by a number of factors, including ability to move, clear 
skin in easily visible parts of the body as well as general 
level of satisfaction. Of course, patients with rheumatic 
disorders have to abstain from several forms of leisure 
especially associated with travelling and sport perfor-
mances, but the predominance of “beneficial” and “very 
beneficial” answers on those items of the questionnaire 
are important proof of enhanced satisfaction in the pa-
tients. There were no significant differences between 
patients suffering from any specific disease (Table IV).
Cumulative evaluation of the effect of biological 
therapy on the patients’ life is summarized in Table V. 
Nine out of ten patients considered the effect of man-
agement as beneficial or very beneficial, and there were 
no differences between groups suffering from various 
diseases.
Disadvantages of biological therapy
Travel to the center is a difficulty and impediment for 
several patients. In general, there are great differences 
in accessibility of the centers within various parts of the 
country. This disadvantage is summarized in Table VI. 
About 40% of the patients considered it as a disadvan-
tage. There were no differences between groups of the 
patients with various diseases except those with juve-
nile idiopathic arthritis. For these patients, travelling to 
a medical center was a slightly more common impedi-
Table IV. Effect of biological therapy on interpersonal relations, sexual life and leisure time
Aspect of life All (%) Rheumatoid 
arthritis (%)
Ankylosing 
spondylitis (%)
Psoriatic arthritis 
(%)
Juvenile idiopathic 
arthritis (%)
Interpersonal relations
Very negative 2 (0.2) 1 (0.2) 0 1 (0.9) 0 
Negative 23 (1.9) 11 (1.8) 7 (1.6) 3 (2.6) 2 (3.2)
No influence 360 (29.6) 198 (32.6) 112 (26.2) 26 (22.2) 24 (38.8)
Beneficial 481(39.7) 240 (39.6) 174 (40.7) 44 (37.5) 23 (37.1)
Very beneficial 300 (24.8) 127 (21.0) 123 (28.9) 40 (34.2) 10 (16.1)
Not applicable 46 (3.8) 29 (4.8) 11 (2.6) 3 (2.6) 3 (4.8)
Sexual life
Very negative 3 (0.2) 1 (0.2) 1 (0.2) 1 (0.9) 0 
Negative 44 (3.6) 28 (4.6) 11 (2.6) 4 (3.4) 1 (1.6)
No influence 390 (32.2) 206 (34.0) 112 (26.2) 42 (35.9) 30 (48.5)
Beneficial 406 (33.5) 187 (30.9) 165 (38.7) 44 (37.6) 10 (16.1)
Very beneficial 220 (18.2) 87 (14.3) 102 (23.9) 21 (17.9) 10 (16.1)
Not applicable 149 (12.3) 97 (16.0) 36 (8.4) 5 (4.3) 11 (17.7)
Leisure time
Very negative 8 (0.7) 3 (0.5) 3 (0.7) 2 (1.7) 0 
Negative 58 (4.8) 34 (5.6) 11 (2.6) 8 (6.8) 5 (8.1)
No influence 296 (24.4) 184 (30.4) 81 (18.9) 23 (19.7) 8 (12.9)
Beneficial 492 (40.6) 246 (40.6) 177 (41.5) 41 (35.0) 28 (45.2)
Very beneficial 358 (29.5) 139 (22.9) 155 (36.3) 43 (36.8) 21 (33.8)
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ment than for those with other disorders requiring bio-
logical therapy.
Blood sampling was found to be a minor disadvan-
tage in most of the patients. More than four-fifths of all 
of them did not consider blood sampling as a problem. 
The only group of patients for whom sampling was some 
problem were those suffering from juvenile idiopathic 
arthritis, although differences between the groups were 
rather small. It is possible that memories of blood sam-
pling from their childhood affected their estimation of 
this phenomenon (Table VI).
Laboratory and imaging tests were considered as an 
inconvenience by a rather a small part of the patients. 
In contrast, the waiting period for biological therapy is 
considered as an important issue by about 40% of the 
patients (Table VI).
About four-fifths of all patients accepted the way of 
administration of biological drugs (Table VI). The high-
Table V. Cumulative patient’s evaluation of the effect of biological therapy on his/her life
Evaluation All (%) Rheumatoid 
arthritis (%)
Ankylosing 
spondylitis (%)
Psoriatic arthritis 
(%)
Juvenile idiopathic 
arthritis (%)
Very negative 4 (0.3) 1 (0.2) 1 (0.2) 2 (1.7) 0 
Negative 46 (3.8) 30 (5.0) 11 (2.6) 4 (3.4) 1 (1.6)
No influence 88 (7.3) 53 (8.7) 19 (4.4) 8 (6.8) 8 (12.8)
Beneficial 598 (49.3) 303 (50.0) 216 (50.6) 48 (41.0) 31 (50.0)
Very beneficial 476 (39.3) 219 (36.1) 180 (42.2) 55 (47.0) 22 (35.6)
Table VI. Selected disadvantages of biological therapy
Disadvantages All (%) Rheumatoid 
arthritis (%)
Ankylosing 
spondylitis (%)
Psoriatic 
arthritis (%)
Juvenile idiopathic 
arthritis (%)
Travel to the medical center
Great impediment 103 (8.5) 47 (7.8) 36 (8.4) 9 (7.7) 11 (17.7)
Impediment 395 (32.6) 199 (32.8) 135 (31.6) 39 (33.3) 22 (35.5)
Unimportant 670 (55.3) 328 (54.1) 244 (57.2) 69 (59.0) 29 (46.8)
I do not know 44 (3.6) 32 (5.3) 12 (2.8) 0 (0.0) 0 (0.0)
Blood sampling during regular check-up visits related to biological therapy
Great impediment 21 (1.7) 8 (1.3) 4 (0.9) 3 (2.6) 6 (9.7)
Impediment 134 (11.1) 69 (11.4) 46 (10.8) 11 (9.4) 8 (12.9)
Unimportant 1057 (87.2) 529 (87.3) 377 (88.3) 103 (88.0) 48 (77.4)
Laboratory and imaging tests required to be started on biological therapy
Significant inconvenience 40 (3.3) 17 (2.8) 19 (4.4) 3 (2.6) 1 (1.6)
Inconvenience 213 (17.6) 88 (14.5) 87 (20.4) 30 (25.6) 8 (12.9)
Unimportant issue 811 (66.9) 409 (67.5) 276 (64.7) 77 (65.8) 49 (79.1)
I do not know 148 (12.2) 92 (15.2) 45 (10.5) 7 (6.0) 4 (6.4)
Waiting period for biological therapy
Significant inconvenience 177 (14.6) 79 (13.0) 70 (16.4) 18 (15.4) 10 (16.1)
Inconvenience 336 (27.7) 145 (23.9) 133 (31.1) 44 (37.5) 14 (22.6)
Unimportant issue 525 (43.3) 266 (44.0) 184 (43.1) 43 (36.8) 32 (46.2)
I do not know 174 (14.4) 116 (19.1) 40 (9.4) 12 (10.3) 6 (9.7)
Way of drug administration
Very negative 3 (0.3) 3 (0.5) 0 0 0 
Negative 84 (6.9) 39 (6.4) 25 (5.9) 8 (6.8) 8 (12.9)
No influence 993 (81.9) 463 (76.4) 363 (85.0) 103 (88.0) 50 (80.6)
I do not know 132 (10.9) 101 (16.7) 39 (9.1) 6 (5.2) 4 (6.5)
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est relative rate of the responders “without influence” 
was in the patients with psoriatic arthritis or ankylosing 
spondylitis. There was a relatively high rate of patients 
with rheumatoid arthritis who responded “I do not 
know”. It may indicate that the parenteral way of ad-
ministration is a generally accepted way of introduction 
of active medicines into the body.
Discussion
It is well known that biological therapy has a pro-
found beneficial effect on quality of life of patients with 
inflammatory rheumatic disorders. The problem of sat-
isfaction or discontent of the patients in reference to 
administration of biological therapy is more complex 
and is affected by a number of factors. The factors are 
of various nature, and include psychological, social and 
economic factors as well as factors related to culture 
and tradition [10, 12]. Most of the factors are specific for 
the country or its region, including such factors as edu-
cation, cultural traditions, economic situation and legis-
lative regulations. Thus, these factors affecting satisfac-
tion of patients are different from the factors affecting 
results of the clinical trials that are evaluating clinical 
efficacy of biological medication only, and the factors 
are specific for various groups of the patients.
The present study is according to our knowledge the 
first such analysis in Poland. The study revealed a rela-
tively beneficial effect of treatment with biologics seen 
as a high level of satisfaction. The differences between 
the subgroups of patients with various disorders were 
shown to be rather minor. Some of them however seem 
to be of interest. The beneficial effect of biological ther-
apy on cutaneous and articular involvement in patients 
suffering from psoriatic arthritis probably explains the 
slightly higher satisfaction of those patients with med-
ication. It is concordant with other studies indicating 
a depressive effect of skin manifestation of the disease 
[18–21]. Younger age of the patients with ankylosing 
spondylitis and administration of biologics in an earlier 
stage of the disease can explain the beneficial effect of 
medication on the sexual life of the patients [13–16]. In 
contrast, patients with a long-lasting disease and sev-
eral chronic malformations or functional alterations 
were less satisfied with the biological therapy. It applied 
mostly to adult patients with juvenile idiopathic arthri-
tis. It should also be underlined that during the study 
the patients did not find a beneficial effect of medica-
tion on their financial situation.
The obtained results are comparable to single reports 
on selected aspects of patients’ satisfaction. Impaired 
social functioning and leisure activities were reported in 
patients with ankylosing spondylitis by van Genderen et 
al. [13]. They suggested the role of support from other 
individuals in amelioration of such impairments. Some 
studies reported that many of the patients with anky-
losing spondylitis are afraid of malfunctioning within 
various areas, including professional activity, family life 
and social functioning [12, 17]. Some studies indicate a 
profound negative impact of ankylosing spondylitis on 
sexual life, especially detectable in male patients [13–
15]. This finding is in agreement with our observation. 
Ku et al. [11] investigated factors influencing the 
level of satisfaction of patients with chronic rheumatic 
diseases and found that the majority of factors are un-
related to the physician or the skills of that physician. 
This finding is also concordant with our finding; howev-
er, knowledge of the nature of the factors affecting the 
satisfaction level of the patients seems to be important 
and despite the conclusion of Ku et al. [11] it is possible 
that the physician has some ability to improve the pa-
tient satisfaction. 
Conclusions
The present study indicates the complexity of the 
problem of patient satisfaction and discontent during 
biological treatment and suggests the need for further 
investigations focused on specific aspects of the prob-
lem. Satisfaction, especially in chronic diseases, has 
an impact on patients’ adherence to medication. Thus 
there is a need to maximize the satisfaction, and of 
course, to measure the patients’ satisfaction in the pro-
cess of medical care.
The authors declare no conflict of interest.
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